The Company

Jupiter Biomedical Research (JBR) was formed on December 29, 2016. The patents for the two product candidates were contributed by Dr. Tucker to the Company on December 30, 2016. On December 30, 2016, the Company also initiated a private placement.

Introduction

JBR is an innovative drug development company having patents for a potential brain cancer (glioblastoma multiforme) therapeutic and for an antiviral treatment for measles virus infection and associated diseases such as multiple sclerosis (MS)and subacute sclerosing panencephalitis (SSPE).  In the short term, the company’s focus will be on preclinical and clinical development of novel drugs for the treatment of brain cancer and other epidermoid tumors.  The long-term strategic direction will encompass treatments for other solid tumor cancers (breast, lung, etc.), neurologic diseases caused by viruses and stem cell technologies. 

With regard to its lead clinical candidate for brain cancer, the Company believes that it has accomplished sufficient preclinical animal testing and in vitro assessments to provide the regulatory required data on the safety and potential efficacy of this product. The Company’s long-term goal for its brain cancer treatment compound is to achieve approval from Health Canada and the US Food & Drug Administration.

Product 1 - Cancer Treatment

The product based upon the first patent referenced above is being advanced as a potential cancer treatment. The product proposed is one which has the potential to treat countless numbers of humans suffering from the deadly disease of brain cancer.  While there are some treatment options presently available, none are effective enough to keep brain cancer from being one of the most frightening and life-threatening diagnosis that can be made.  Management believes that the drugs being developed by the Company have the potential to significantly affect the treatment of brain cancer. The science, drug testing, and protocol has been in development for over 30 years. It is only the last three years that the intellectual property has been protected by issued patents. Management now feels confident that we can move forward to begin regulatory compliance trials knowing that we have intellectual property protection.

Product 2 - Antiviral Treatment

The antiviral product developed by Dr. Tucker is focused upon multiple sclerosis (MS) and SSPE. MS is characterized by acute exacerbations of neurological dysfunction with inter-current periods of improvement and quiescence. SSPE is a progressive, fatal disease of young children, directed at the Central Nervous System (CNS) caused by a persistent measles virus. The Company’s anti-viral drug, which we refer to as “Avir“ is patented for treatment of Subacute Sclerosing Pan Encephalitis (SSPE) and Multiple Sclerosis (MS).